Soluble beta-1,3/1,6-glucan

Drug Profile

Soluble beta-1,3/1,6-glucan

Alternative Names: SBG; Soluble beta-glucan; Woulgan

Latest Information Update: 15 Sep 2015

Price : $50

At a glance

  • Originator Biotec Pharmacon
  • Class Antineoplastics; Beta Glucans
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stomatitis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer; Stomatitis

Highest Development Phases

  • No development reported Breast cancer; Inflammatory bowel diseases; Influenza virus infections; Neuroblastoma; Non-Hodgkin's lymphoma; Stomatitis
  • Discontinued Diabetic foot ulcer

Most Recent Events

  • 15 Sep 2015 No recent reports on development identified - Phase-I for Non-Hodgkin's lymphoma (Combination therapy) in Norway (PO)
  • 15 Sep 2015 No recent reports on development identified - Phase-I/II for Neuroblastoma (Combination therapy, In children) in USA (PO)
  • 15 Sep 2015 No recent reports on development identified - Preclinical for Inflammatory bowel disease in Norway (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top